Research topics
Microbiome articles covering gut bacteria, microbial changes, microbiota research, and IBD disease mechanisms.
Page 1 of 12 · 569 articles
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Microbiome, and Research and clinical trials. The original article is from Communications Medicine.
The paper describes a plant-derived polysaccharide that reduced inflammation, improved barrier proteins, and shifted gut microbiota in a mouse model of ulcerative colitis—mechanisms relevant to IBD. If replicated and...
If probiotic strains can increase beneficial microbial metabolites that strengthen the gut barrier and reduce inflammation, they could point to new adjunctive strategies for IBD treatment.
The study suggests a specific mechanism—modulation of the SphK1/S1P/NF-κB pathway—by which components of a traditional herbal formula may reduce intestinal inflammation and influence the gut microbiome. If validated in...
The study identifies a prebiotic-encapsulated extracellular vesicle approach that reduced colitis severity and early kidney stress in a mouse model, pointing to the gut microbiota and barrier function as key mediators....
The study suggests two different ways to reduce inflammation in a mouse model of ulcerative colitis—one using a plant-derived compound that shifts beneficial microbes and metabolites, the other using an antibiotic that...
The study suggests a specific immune pathway (NOX2-driven ROS in M1-like macrophages) by which colitis can worsen periodontitis, pointing to a potential therapeutic target that could eventually benefit people with IBD...
Findings suggest a dietary-derived prebiotic (Poria cocos polysaccharides) may reduce experimental colitis by shifting the microbiome and bile acids toward anti-inflammatory signaling—an avenue that could inform future...
If epithelial cells keep lasting "memories" of past inflammation or microbial signals, that could help explain why some people with IBD have persistent barrier dysfunction, relapses, or incomplete mucosal recovery even...
This study tests a novel method to deliver healthy mitochondria to the gut lining and reports improved cellular energy, barrier function, and decreased oxidative stress in a mouse model of ulcerative colitis—suggesting a...
This preclinical study describes a new cell‑based approach — macrophages engineered to secrete IL‑10 — that reduced inflammation and improved colon outcomes in a mouse colitis model, suggesting a potential avenue for...
If oral microbes can influence the gut, that could open new ways to monitor or modify disease activity in IBD (for example saliva-based biomarkers or oral-targeted interventions). It also highlights modifiable factors...
The study suggests postbiotics from a gut bacterium can reduce inflammation in a mouse colitis model and identifies a candidate metabolite and signaling pathway that could be targeted in future IBD research.
The findings describe a novel cell‑based IL‑10 delivery strategy that reduced experimental colitis and altered gut microbiota—an approach that could inform future IBD therapies research.
The work helps explain why people with IBD often have unstable gut microbiomes and limited recovery of beneficial bacteria, linking those patterns to inflammation — which is relevant for efforts to develop...
This review connects enteric sensory neuron dysfunction to symptoms common in IBS and IBD (pain, diarrhea, constipation, dysmotility). Understanding IPAN plasticity could point to new treatment targets that act locally...
Findings suggest a dietary flavonoid (daidzein) may reduce colitis in mice via microbial activation and host signaling pathways, pointing toward microbiome-informed nutritional approaches for IBD.
The review identifies berberine as a potential adjunct therapy for UC because it may target both gut microbes and epithelial inflammasome-mediated cell death, processes important in disease activity and barrier function.
If true, a commonly available dietary change—drinking alkalinised filtered water—might modestly affect inflammatory markers and specific gut bacteria in people with IBD in remission, which could be of interest to...
The gut microbiome and its metabolic pathways are areas of active research in IBD; this study suggests specific genera and predicted functions that could become candidate biomarkers or targets for follow-up studies.
The study links microbiome metabolites to reduced epithelial inflammation and improved barrier function via AhR and cholinergic pathways—mechanisms relevant to IBD. This could guide future preclinical and therapeutic...
This trial explores whether delivering sodium propionate directly to the colon can alter the gut microbiome and immune markers in people with Crohn’s disease and whether it offers similar or added benefits compared with...
Researchers identified a plant-derived compound that reduced inflammation, oxidative stress, and gut dysbiosis in a mouse model of ulcerative colitis; this could point to new mechanistic leads for future therapies...
The review identifies PPARγ as a key molecular hub in ulcerative colitis and compiles preclinical evidence that natural compounds can modulate PPARγ-related networks—suggesting possible new therapeutic directions that...
This review compiles preclinical evidence that propolis (a natural bee product) reduced inflammation and improved gut barrier and microbiota in animal models of colitis, so it may be a candidate for future clinical...
This study identifies a compound that improved inflammation, barrier integrity, and microbiome/metabolite signatures in a mouse model of ulcerative colitis—areas that matter for symptom control and disease biology in...
This study highlights a potential microbiome–bile acid–immune pathway that could be relevant to ulcerative colitis and suggests a traditional herbal formula may influence that pathway in mice. Patients interested in...
Identifying a blood biomarker that appears before symptoms could help find people at higher risk for Crohn’s disease and improve understanding of early disease processes. This could inform earlier monitoring or future...
People with ulcerative colitis may be interested because the study suggests a combined probiotic approach could strengthen gut bacteria functions linked to a protective metabolite (spermidine) and reduce colitis-like...
A preclinical mouse study found that heat-inactivated Lacticaseibacillus paracasei PC-01 reduced colitis signs and altered gut microbiota, which may be of interest for microbiome-targeted IBD research but does not show...
This preclinical study identifies a parasite-derived fluid that reduced inflammation, oxidative stress, and microbiome disruption in a mouse model of ulcerative colitis and in intestinal cells, pointing to possible new...
This study suggests coconut oil and its myristic acid component reduced Crohn’s-like inflammation in a mouse model via effects on the microbiome and regulatory T cells, which could point toward new dietary or adjunctive...
This study tested a blood biomarker (zonulin) tied to gut barrier function and found no evidence of increased intestinal permeability in these Behçet syndrome patients, unlike in the Crohn’s disease group.
Multi-omics and AI approaches could improve biomarker discovery and predictive models that matter for earlier diagnosis and personalised treatment strategies in IBD, but practical use is limited today by data and...
An experimental mouse study suggests gastrodin may reduce colitis severity and associated anxiety/depression-like behaviours while changing gut microbiota, metabolites, and intestinal inflammation — an early preclinical...
The article discusses peptide compounds that people with Crohn’s and other IBDs are exploring for gut barrier support and inflammation — a topic many patients consider when seeking adjunctive or experimental approaches.
FMT is shown here to be an effective option for treating recurrent C. difficile infection, including for patients who also have IBD — a group often vulnerable to recurrent infections and complications.
Understanding microbiota–neuroimmune interactions could explain why symptoms like urgency and pain persist in some people with UC and may point to new treatment strategies that go beyond conventional anti-inflammatory...
This study suggests a plant extract (Macleaya cordata) and its component sanguinarine reduced inflammation and improved colitis signs in mice by changing gut bacteria and macrophage activation — mechanisms relevant to...
Purinergic signaling connects nerves, immune cells, epithelium, and microbiota in the gut — pathways that can influence inflammation, motility, and pain relevant to IBD. Understanding these mechanisms could point to new...
The work suggests new molecular readouts (fecal metaproteomics and lysine crotonylation) that could help explain why some people with ulcerative colitis respond to FMT while others do not, potentially guiding future...
People with Crohn’s disease or ulcerative colitis may have higher cardiovascular risk; this prospective study aims to measure how often major heart and vascular events occur in IBD and to find biological and clinical...
First-person stories can help people with Crohn’s disease feel less alone and show ways to turn a diagnosis into advocacy or research involvement. The article highlights pediatric-to-adult transition issues and patient...
The study identifies ABCA1 deficiency and epithelial cholesterol accumulation as drivers of colonic injury and inflammation in a hamster model, highlighting a possible new mechanism relevant to IBD pathogenesis. That...
Based on the title and source metadata, this appears to be a conference abstract related to Crohn's disease, Inflammatory bowel disease, and Microbiome. The original article is from Anais do XI Congresso Médico...
The paper suggests a new animal model linking syndromic albinism mutations, intestinal inflammation, and gut-microbiome changes—areas relevant to understanding IBD biology and potential microbiome-targeted interventions.
This preclinical work suggests the gut microbiota and tryptophan-derived metabolites that activate AhR may be important in reducing colitis-related inflammation — a potential route for future therapies relevant to...
The study suggests a dietary protein (ovotransferrin) can reduce colitis severity in mice by changing the gut microbiota and increasing certain secondary bile acids that lower inflammation and gut permeability.
